Molecular processes driving psychosis in Alzheimer’s disease

Blood-based brain-derived tau in Alzheimer’s disease

Role of platelet aggregation in dementia risk

Current research into NK cell therapy and the potential for use in other conditions

Hearing loss and dementia: peripheral vs central aspects

Amyloid prediction models for use in the general population

Roadblocks to the use of blood-based biomarkers in clinical care

Increasing participation of underrepresented groups in clinical trials

Visual versus quantitative analysis of tau-PET

Why Alzheimer’s disease research is focusing on tau

The promise of tau aggregation inhibitors in dementia

Blood-based biomarkers for treatment monitoring in Alzheimer’s disease

Barriers to participation of underrepresented groups in clinical trials

Genes differentially associated with Alzheimer’s disease based on sex and APOE status

The Phase III LUCIDITY trial: a tau aggregation inhibitor in patients with Alzheimer’s disease

Advantages of tau-PET compared to amyloid-PET